Analyst Price Target is $0.00
This price target is based on 0 analysts offering 12 month price targets for AltheaDx in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a NaN upside from the last price of $0.00.
Current Consensus is
The current consensus among 0 investment analysts is to n/a stock in AltheaDx. This N/A consensus rating has held steady for over two years.
AltheaDx, Inc. is a United States-based commercial-stage molecular diagnostics company. The Company is specialized in the field of pharmacogenetics. The Company focuses on enabling physicians, managed care organizations, pharmaceutical companies and other healthcare entities to make personalized therapeutic decisions for patients. The Company’s IDgenetix pharmacogenetic testing portfolio addresses various clinical conditions in the United States, including cardiovascular disease, neuropsychiatric disorders and pain. The IDgenetix testing process consists of three steps: drug metabolism genotyping, drug response genotyping and algorithm screening. Its algorithm-based bioinformatic platform and pharmacogenetics product testing portfolio are intended to serve as a tool to assist healthcare providers in identifying optimal drugs for their patients, as well as dosing guidelines based on a patient’s genetic make-up, prescription regimen and other key factors.